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Introduction {#sec001}
============

We and others have previously reported a method to induce loss of heterozygosity (LOH) in mouse embryonic stem cells (ESCs) under suppression of the Bloom syndrome (*Blm*) gene \[[@pone.0225740.ref001]\] \[[@pone.0225740.ref002]\] \[[@pone.0225740.ref003]\]. Suppression of *Blm* enhanced the rate of mitotic recombination, and crossovers occurred randomly across the observed chromosome \[[@pone.0225740.ref004]\]. When DNA double-stranded breaks (DSBs) were introduced by meganuclease I-SceI under *Blm* suppression, the rate of LOH was further enhanced by crossovers at sites close to the allele-specific I-SceI-cutting site \[[@pone.0225740.ref004]\]. We analyzed mouse ESC clones after generating the crossovers and found that LOH occurred across entire genomic regions from crossover points to telomeres.

To date, a system that induces LOH in a targeted region on a specific chromosome in cells, such as human induced pluripotent stem cells (hiPSCs), has not been established yet. We hypothesized that a feasible method to generate region-specific LOH in hiPSC lines would be as follows. Assuming that parental hiPSCs bear a heterozygous mutation on the target chromosome and an allele-specific DSB is introduced on that chromosome during the 4N stage of the cell cycle, the genomic region from the site of the DSB to the telomere would contain either a homozygous mutation or no mutation after crossover and chromosome segregation ([Fig 1A](#pone.0225740.g001){ref-type="fig"}). This phenomenon can then be used to identify genes responsible for certain diseases. When the mutation "X" is a dominant mutation (parental hiPSCs have the disease phenotype), some of the clones do not have the disease phenotype after crossover (case \#b in [Fig 1A](#pone.0225740.g001){ref-type="fig"}). However, when X is a recessive mutation (parental hiPSCs do not have the disease phenotype), some of the clones have the disease phenotype after crossover (case \#a in [Fig 1A](#pone.0225740.g001){ref-type="fig"}).

![Establishment of a *BLM* transcript regulation system and detection of crossovers by a reporter cassette in hiPSCs.\
(A) Schematic representation of a crossover induced by a double-stranded DNA break during the 4N stage of the cell cycle in hiPSCs. X is a dominant mutation. After segregation, case \#a cells have the disease phenotype, while case \#b cells are normal. (B) Targeting of the Tet-Off cassette to both alleles of the *BLM* locus with the assistance of TALEN (*BLM*^tet-puro/tet-puro^). The selection cassettes were removed by Flippase (Flpo), the hiPSC-*BLM*^*tet/tet*^ cells were established. (C) Electrophoresis of qRT-PCR products. Total RNA from 2 × 10^5^ hiPSC-*BLM*^tet/tet^ cells was collected at days 0, 5, and 7 after dox treatment, and qRT-PCR was performed. (D) Histogram data represent the mean ± SEM of three independent experiments. Comparison of two groups with normally distributed variables was performed using the Student's *t*-test by Kaleida Graph software. (E) Targeting of the double selection cassette (*cNP*) to the AAVS1 locus (hiPSC-*BLM*^*tet/tet*^*AAVS*^*cNP/+*^). (F) Schematic representation of mitotic crossover during the 4N stage. DSBs were introduced by CRISPR/Cas9.](pone.0225740.g001){#pone.0225740.g001}

This study revealed that both allele-specific DSBs mediated by CRISPR/Cas9 and *BLM* suppression allow targeted homozygosity in hiPSCs. Therefore, this system is applicable to in vitro genetic analysis of hiPSCs, when crossbreeding experiments are not possible.

Methods {#sec002}
=======

Vector construction {#sec003}
-------------------

*BLM*-targeting vector: To prepare the human *BLM-*targeting vector, we changed the *tk* promoter to the *hPGK* promoter and modified the Kozak sequence for tTA translation from AGGATT to GCCACC in the mouse *Blm*-targeting vector \[[@pone.0225740.ref001]\]. We also removed the artificial intron sequence from the mouse *Blm-*targeting vector \[[@pone.0225740.ref001]\]. The left and right arms of the targeting vector were prepared by PCR using primers hBLMLarmF1 and hBLMLarmR1, and hBLMRarmF1 and hBLMRarmR3, respectively ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). Chromosome 19 *AAVS1*-vector construction with the cNP cassette: The cNP cassette used in this study was derived from the cNP cassette used in mouse ESCs \[[@pone.0225740.ref002]\] with the following three modifications. The *Pgk* promoter was changed to the *hEF1α promoter*, the *Δtk g*ene was removed, and *Lox2272*s were replaced by *loxP*s. The left and right arms of the targeting vector were prepared by PCR using primers AAVS1-LF1 and AAVS1-LR1, and AAVS1-RF1 and AAVS1-RR1, respectively ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). Chromosome 6 HLA region-targeting vector with cNP in PB: The insulator sequence (`TGCTTGTCCTTCCTTCCTGTAACACAGCCATTAAACCAGGAGCATCGCCCTTCCCCGGCCCTCAGGTAAGAGGACCAAATACCGTAGCCGTTTCCAATTTCAGTCCTTTAGCGCCACCTGGTGCTAACTACTCTATCACGCTTTTATCCAATAACTACCTTTGTAAATTTCCTTTCAAAAGTTCTGGCCGGGCGCGGTGGCTCACGCTTGTAATCCCAGCACTTTGTGAGGGGTCAGGAGTTC`; chromosome 7, bp 39519983--39520225: GRCh38) \[[@pone.0225740.ref005]\] was flanked by the cNP cassette. The insulator and cNP cassette were inserted into the piggyBac transposon vector \[[@pone.0225740.ref006]\], resulting in the cNP in PB. The left and right arms of the targeting vector were prepared by PCR using primers chr6-Asc1-up and chr6-Asc1-low, and chr6-Pac1-up and chr6-Pac1-low, respectively ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). The iCre gene was expressed under the control of the EF1*α* promoter.

Cell culture {#sec004}
------------

hiPSC lines \[[@pone.0225740.ref007]\] were grown in hESC serum-free human ESC (hESC) medium consisting of DMEM/F-12 (Life Technologies) supplemented with 20% knockout serum replacement (Life Technologies), 2 mM L-glutamine, 1× nonessential amino acids (Life Technologies), 0.1 mM 2-mercaptoethanol, and 5 ng/mL basic fibroblast growth factor (Katayama Chemical Industries) on Synthemax II-SC-coated tissue culture dishes (Corning). The cells were passaged using Accutase (Sigma) and seeded with the Rho kinase inhibitor Y-27632 (10 μM; LC Laboratories).

Targeting {#sec005}
---------

To target the *BLM* locus, hiPSCs were transfected as a single cell suspension by electroporation (Neon Transfection System; Invitrogen) using 1 × 10^6^ cells in a 100 μL tip with 8 μg total DNA (TALEN left, 2 μg; TALEN right, 2 μg; *BLM*-targeting vector, 4 μg). TALEN sequences are shown in [S2 Table](#pone.0225740.s011){ref-type="supplementary-material"}. After one pulse of electroporation at 1,100 V with a 30 ms pulse width, the cells were plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing 10 μM Y-27632 without puromycin. Selection was initiated with 0.5 μg/mL puromycin at 2 days after transfection. The targeted clones were first selected by PCR with primers hBLM-3 and tTA2, and then the targeted biallelic clones (*BLM*^*tet/tet*^ hiPSCs) were chosen by PCR with primers hBLM-1, hBLM-2, and tTA-1. Then, the selection cassettes were removed by Flippase (Flpo), and the hiPSC-*BLM*^*tet/tet*^ cells were thereby established ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). To target the *AAVS1* locus, *BLM*^*tet/tet*^ hiPSCs were transfected as a single cell suspension by electroporation using 1 × 10^6^ cells in a 100 μL tip with 8 μg total DNA (*AAVS1-ZFN* left, 2 μg; *AAVS1-ZFN* right, 2 μg; *AAVS1*-targeting vector, 4 μg). The AAVS1-ZFN sequences have been described previously \[[@pone.0225740.ref008]\]. After one pulse of electroporation at 1,200 V with a 30 ms pulse width, the cells were plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing 10 μM Y-27632 without G418. Selection was initiated with 100 μg/mL G418 at 2 days after transfection. The targeted clones were first selected by PCR with primers AAVS1-LF2 and Puro-L2, and then the targeted monoallelic clones (*BLM*^*tet/tet*^ *AAVS1*^*cNP/+*^hiPSCs) were chosen by PCR with primers AAVS1-C-F, AAVS1-C-R, and Puro-L2 ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). To target the telomeric region of the short arm of chromosome 6, hiPSCs were transfected as a single cell suspension by electroporation using 1 × 10^6^ cells in a 100 μL tip with 8 μg pX330 (AGAAAATAGCCGCCACTTAA as the gRNA) and 3.5 μg HLA-targeting vector with cNP in PB. After one pulse of electroporation at 1,200 V with a 30 ms pulse width, the cells were plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing 10 μM Y-27632. Selection was initiated with 100 μg/mL G418 at 2 days after transfection. The concentration of G418 was increased to 150 μg/mL at 4 days post-transfection. The targeted clones were first selected by PCR with primers chr6-TG-up and hEF1a-TG, and then the targeted monoallelic clones (*telHLA*^*cNP/+*^hiPSCs) were chosen by PCR with the primers chr6-TG-up, chr6-TG-low, and hEF1a-TG ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}).

Introduction of allele-specific DSBs in chromosome 19 {#sec006}
-----------------------------------------------------

*BLM*^*tet/tet*^*AAVS1*^*cNP/+*^ hiPSCs were transfected as a single cell suspension by electroporation using 1 × 10^6^ cells in a 100 μL tip with 9.5--11 μg total DNA (6.5--8.0 μg pX330 containing various gRNA sequences and 3 μg iCre recombinase plasmid). *BLM*^*tet/tet*^*AAVS1*^*cNP/+*^ hiPSCs were pretreated with dox (1 μg/mL) from 7 days before transfection. The gRNA sequences are listed in [S3 Table](#pone.0225740.s012){ref-type="supplementary-material"}. After one pulse of electroporation at 1,300 V with a 20 ms pulse width, the cells were plated on Synthemax II-SC-coated tissue culture dishes in hESC medium containing 10 μM Y-27632 without puromycin or G418. At 2 days after transfection, selection was initiated with 0.5 μg/mL puromycin. At 4 days after transfection, the selection condition was changed to 1 μg/mL puromycin and 100 μg/mL G418. At 6 days after selection, the G418 concentration was increased to 200 μg/mL G418.

Introduction of allele-specific DSBs in chromosome 6 {#sec007}
----------------------------------------------------

*telHLA*^*cNP/+*^ hiPSCs were transfected using the same protocol for chromosome 19. The gRNA sequences are listed in [S3 Table](#pone.0225740.s012){ref-type="supplementary-material"}. ML216 (12.5 μM) was applied from 12 h before transfection until 2 days after transfection. At 2 days post-transfection, selection was initiated with 0.2 μg/mL puromycin. At 4 days post-transfection, the selection condition was changed to 0.25 μg/mL puromycin and 25 μg/mL G418. At 6 days after selection, the selection condition was changed again to 0.33 μg/mL puromycin and 50 μg/mL G418.

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR) {#sec008}
-----------------------------------------------------------------------------

Total RNA was extracted from cells with an RNeasy Plus Micro Kit (Qiagen). First-strand cDNA was synthesized from 800 ng total RNA with random hexamer primers using SuperScript III (Invitrogen) at 50°C for 60 min. qRT-PCR was performed to measure *BLM* gene expression. Total RNA was reverse transcribed to cDNA using the SuperScript III First-Strand Synthesis System for qRT-PCR (Invitrogen). qRT-PCR was performed with the Applied Biosystems 7900HT Fast Real-Time PCR System using the following PCR primer sets: RTPCR-leader-F and RTPCR-exon3-R, hActb-RTPCR-F, and hActb-RTPCR-R ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}).

Quantification of pluripotency marker gene expression {#sec009}
-----------------------------------------------------

Total RNA was isolated from parental fibroblasts, hiPSC-*telHLA*^*cNP/+*^, and hiPSC-*telHLA*^*cNP/+*^ML216(+)HLA I-III-CRISPR(+). Library preparation was performed using a TruSeq stranded mRNA sample prep kit (Illumina, San Diego, CA), according to the manufacturer's instructions. Whole transcriptome sequencing was applied to the RNA samples through Illumina HiSeq 2500 and 3000 platforms in the 75-base single-end mode. Illumina Casava ver.1.8.2 software was used for base calling. The sequenced reads were mapped to human reference genome sequences (hg19) using TopHat ver. 2.0.13 in combination with Bowtie2 ver. 2.2.3 and SAMtools ver. 0.1.19. The number of fragments per kilobase of exon per million mapped fragments (FPKM) was calculated using Cufflinks ver. 2.2.1. The FPKM values were calculated from the respective sequence data, and the analyses were performed using iDEP85 (<http://bioinformatics.sdstate.edu/idep/>). The SNP-array data have been deposited in the Genomic Expression Omnibus under accession number (GSE134441,GSE137657, GSE138093).

Screening for positive clones with crossover occurring in chromosomes 19 and 6 {#sec010}
------------------------------------------------------------------------------

DNA was extracted from hiPSCs with a DNeasy Blood & Tissue Kit (Qiagen). Competitive PCR was performed to detect positive clones of chromosome 19 using primers AAVS1-C-F, AAVS1-C-R, and Puro-L2 ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). Cycling conditions were initial denaturation at 94°C for 2 min, followed by 35 cycles of 98°C for 10 s, 68°C for 90 s, and 72°C for 7 min. The wildtype allele was detected at 275 bp, the neomycin-selective allele was detected at 407 bp, and the puromycin-selective allele was detected at 1,435 bp ([S1 Fig](#pone.0225740.s001){ref-type="supplementary-material"}). We performed the same screening for positive clones of chromosome 6 using primers chr6-TG-up, chr6-C-low, and Puro-L2 ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). The wildtype allele was detected at 924 bp, the neomycin-selective allele was detected at 1,355 bp, and the puromycin-selective allele was detected at 2,264 bp (data not shown).

Determination of crossover points in chromosomes 19 and 6 {#sec011}
---------------------------------------------------------

First, we identified heterozygous SNPs by referring to the SNP database dbSNP <https://www.ncbi.nlm.nih.gov/snp> ([S4 Table](#pone.0225740.s013){ref-type="supplementary-material"}). After identifying positive clones by competitive PCR, we extracted the genomic DNA and analyzed the crossover points ([S4 Table](#pone.0225740.s013){ref-type="supplementary-material"}). We defined the crossover points as the positions equidistant from the heterozygous and homozygous SNPs.

HLA genotyping {#sec012}
--------------

First, target DNA was amplified by PCR using group-specific primers LABType SSO HLA A Locus, LABType SSO HLA B Locus, LABType SSO HLA C Locus, and LABType SSO HLA DRB1. The PCR products were biotinylated, allowing detection with R-phycoerythrin-conjugated streptavidin. The PCR products were denatured and allowed to rehybridize to cDNA probes conjugated with fluorescently coded microspheres (One Lambda). A LABScan 100 flow analyzer (One Lambda) identified the fluorescence intensity of phycoerythrin on each microsphere. HLA alleles or allele groups were determined in the sample by matching the pattern of positive and negative bead IDs with the information in the LABType SSO worksheet or using HLA Fusion 4.1 HotFix 2 (both from One Lambda).

Flow cytometry {#sec013}
--------------

hiPSC suspensions were washed with phosphate-buffered saline containing 1% (w/v) bovine serum albumin and 0.05% (v/v) sodium azide and then incubated with the appropriate antibodies for 30 min in the dark on ice. Samples were analyzed on a BD FACSCanto II (BD Biosciences). Data were analyzed with FlowJo software (Tomy Digital Biology). The antibodies used for flow cytometry were a FITC-conjugated anti-HLA-A2 antibody (343303; BioLegend), anti-HLA-A32/25 monoclonal IgM antibody (0136HA; One Lambda), and Alexa Fluor 647-conjugated goat anti-mouse IgM (ab150123; Abcam).

SNP array analysis {#sec014}
------------------

To analyze the SNP copy number, genomic DNA was isolated from parental fibroblast, hiPSCs, hiPSC-*BLM*^*tet/tet*^*AAVS1*^*cNP/+*^, hiPSC-*BLM*^*tet/tet*^*AAVS1*^*cNP/+*^--Dox(+)9M-CRISPR(+),--Dox(+)14M-CRISPR(+),--Dox(+)19M-I-CRISPR(+),--ML216(+)9M-CRISPR(+),--ML216(+)14M-CRISPR(+),--ML216(+)19M-I-CRISPR(+), and hiPSC-*telHLA*^*cNP/+*^ML216(+)HLA I-III-CRISPR(+) and hybridized to an Infinium Omni5-4 v1.2 BeadChip (Illumina). Data were analyzed using GenomeStudio (Illumina). The SNP array data have been deposited in the Genomic Expression Archive under accession number E-GEAD-283.

Results {#sec015}
=======

Establishment of a *BLM* transcript regulation system and detection of crossovers by a reporter cassette in hiPSCs {#sec016}
------------------------------------------------------------------------------------------------------------------

A Tet-Off cassette was used for transient suppression of *BLM* expression. The Tet-Off cassette used for mouse ESCs \[[@pone.0225740.ref001]\] was modified and inserted into both alleles of the *BLM* locus with the assistance of transcription activator-like effector nucleases (TALENs) followed by removal of the selection cassette ([S1 Fig](#pone.0225740.s001){ref-type="supplementary-material"}), resulting in the BLM^tet/tet^ allele ([Fig 1B](#pone.0225740.g001){ref-type="fig"}). The level of BLM transcripts in BLM^tet/tet^ hiPSCs without the addition of doxycycline (dox) was equivalent to that observed in parental hiPSCs ([S2 Fig](#pone.0225740.s002){ref-type="supplementary-material"}) The BLM expression level was then checked at 7 days after the addition of 1 μg/mL dox, and BLM transcripts were measured by quantitative PCR (qPCR). The transcripts in BLM^tet/tet^ hiPSCs were downregulated to 20% of that in the control ([Fig 1C and 1D](#pone.0225740.g001){ref-type="fig"}). We also performed 8 days of treatment with 1 μg/mL dox and found that the level of BLM transcripts was approximately 15% of that in the control ([S3 Fig](#pone.0225740.s003){ref-type="supplementary-material"}), and BLM^tet/tet^ hiPSCs appeared to be unhealthy with longer exposure to dox. Thus, we chose 7 days of treatment with dox.

To detect crossover events in the hiPSCs, a conditionally convertible selection cassette (cNP) was first inserted at the safe-harbor AAVS1 locus of chromosome 19, resulting in the BLM^tet/tet^ AAVS1^cNP/+^ allele ([Fig 1E](#pone.0225740.g001){ref-type="fig"}) \[[@pone.0225740.ref002]\]. The cNP cassette included neomycin (N) and puromycin (P) resistance genes. The N and P genes were arranged in a tail-to-tail configuration and flanked by inversely oriented loxP sequences. Under the default condition, the promoter in front of N drove expression of N but not P, resulting in G418-resistant and puromycin-sensitive hiPSCs (N^R^P^S^). Upon codon-improved Cre recombinase (iCre) expression, inversion of the cNP cassette occurred, resulting in loss of G418 resistance and gain of puromycin resistance. We used iCre to enhance Cre-mediated cassette inversion \[[@pone.0225740.ref009]\]. The iCre-mediated cassette inversion was estimated by surviving colonies after the drug selections ([S4 Fig](#pone.0225740.s004){ref-type="supplementary-material"}). Since the surviving colonies with puromycin were approximately 20%-30% of those with G418, the efficiency of the inversion was 20%-30%. Next, allele-specific DSBs mediated by the CRISPR/Cas9 system were introduced centromeric to the cNP cassette. If crossover occurred in the chromosome bearing the cNP cassette during the 4N stage of the cell cycle, the cNP cassette would be duplicated after segregation ([Fig 1F](#pone.0225740.g001){ref-type="fig"}). These cassette-duplicated cells were selected by both G418 and puromycin after Cre-mediated recombination (N^R^P^R^).

This positive selection approach differs from the negative selection used previously, based on loss of genes encoding herpes simplex virus thymidine kinase (TK) or green fluorescent protein (GFP). Recently, Sadhu et al. reported that negative selection based on loss of the *gfp* gene successfully identified yeast clones bearing LOH following the introduction of allele-specific DSBs with the CRISPR/Cas9 system \[[@pone.0225740.ref010]\]. LOH is often associated with genomic deletion in mammalian cells, and negative selection cannot exclude clones bearing these deletion events \[[@pone.0225740.ref004]\]. In fact, Riolobos et al. reported that an HLA-homozygous cell line was derived from an HLA-heterozygous human ESC line by negative selection with TK, but the efficiency of crossover events was unexpectedly low \[[@pone.0225740.ref011]\]. Although they eventually determined the crossover point, it could not be predicted by their system. In contrast, positive selection is able to exclude deletion events. However, it cannot exclude aberrant cassette duplication due to chromosomal or locus amplifications without crossover \[[@pone.0225740.ref002]\]. However, such aberrant events can be evaluated by competitive PCR to detect whether the wildtype allele is present ([S5 Fig](#pone.0225740.s005){ref-type="supplementary-material"}).

Generation of clones with crossovers in chromosome 19 {#sec017}
-----------------------------------------------------

Preliminary experiments were performed on chromosome 19 where the cNP cassette was inserted at the AAVS1 locus. To introduce allele-specific DSBs, we first searched for SNPs in sequences corresponding to that of the protospacer adjacent motif (PAM) and then designed a single guide RNA (sgRNA) for CRISPR/Cas9. The locations of the allele-specific DSBs were 9, 14, and 19 Mb from the centromere of chromosome 19. The overall procedure used to isolate the positive clones is shown in [Fig 2A](#pone.0225740.g002){ref-type="fig"}.

![Generation and analyses of clones with crossovers in chromosome 19.\
Procedure for the isolation of *N*^*R*^*P*^*R*^ clones under the condition of *BLM* transcript suppression. hiPSC-*BLM*^tet/tet^*AAVS1*^cNP/+^ cells were treated with or without dox from 7 days before transfection to the day of transfection. Selection started 2 days after transfection, either with or without the introduction of an allele-specific DSB. (B) Efficiency of crossover under the various conditions at the 9 Mb region of chromosome 19. We picked 439 colonies (eight trials) and performed genotyping ([S5 Fig](#pone.0225740.s005){ref-type="supplementary-material"}). Bar indicates SEM. (C) Distribution of crossover points at 9 Mb from the centromere of chromosome 19. Twenty-five *N*^*R*^*P*^*R*^-positive clones were isolated and analyzed using LOH panels and SNP arrays. Open squares indicate the heterozygous genotype. Closed black squares indicate the loss of heterozygosity (LOH) genotype. The DSBs introduced by the CRISPR/Cas9 system are indicated by scissors. (D) A schematic representation of chromosome 19 is shown at the top of the figure. After crossover, SNP array analysis indicated that the genome derived from hiPSC-*BLM*^*t*et/tet^*AAVS1*^cNP/+^ Dox(+)9M-CRISPR(+) cells showed homozygosity telomeric to DSB and that the cells maintained two copies of the genome.](pone.0225740.g002){#pone.0225740.g002}

Suppression of *BLM* transcripts by dox started at 7 days before transfection, and selection was performed by gradually increasing the G418 and puromycin concentrations ([Fig 2A](#pone.0225740.g002){ref-type="fig"}). Because we wanted to eliminate hiPSCs that did not undergo iCre-mediated inversion, we started puromycin selection before the double selection. First, we compared various conditions, *BLM* suppression only, DSBs at 9 Mb only, and the combination of *BLM* suppression and DSBs at 9 Mb, to acquire positive clones with possible crossover. As shown in [Fig 2B](#pone.0225740.g002){ref-type="fig"}, we obtained positive clones only when combining *BLM* suppression and DSBs. These results were strikingly different from the previously reported data. In yeast, positive clones with crossovers were obtained by CRISPR-mediated DSBs without suppression of the *BLM* homolog *Sgs1* \[[@pone.0225740.ref010]\]. Moreover, whereas we could not obtain positive clones by *BLM* suppression only, Yamanishi et al. reported that *Blm* suppression alone was sufficient to induce crossover in mouse ESCs. These contrasting results between hiPSCs and mouse ESCs may be due to either the differing efficiency of *BLM*/*Blm* suppression, the differing characteristics of the used cell lines (hiPSCs vs. mouse ESCs), or both. Incomplete suppression of *BLM* may also be a reason for the low number of colonies.

We next analyzed crossover points after the introduction of DSBs and *BLM* suppression. The parental hiPSC line had many heterozygous SNPs along each chromosome, and crossover points should have occurred between SNP-heterozygous and -homozygous (LOH) sites. We tentatively defined crossover points equidistant to the SNP-heterozygous and -homozygous (LOH) sites. We detected crossover points close to the DSB sites at the chromosomal level ([S6A Fig](#pone.0225740.s006){ref-type="supplementary-material"}). As shown by the LOH panel in [Fig 2C](#pone.0225740.g002){ref-type="fig"}, more detailed analyses at the 9 Mb position revealed that, when crossover occurred centromeric to the DSBs, the distance between the crossovers and DSBs was relatively small (\~20 kb). Note that, because all clones were derived from different dishes of cells, clones \#1--\#8 were an independent clone. In contrast, when crossover occurred telomeric to the DSBs, this distance was relatively large (\~300 kb). Clone \#25 was exceptional and probably derived from uniparental disomy or a spontaneous DSB close to the centromere, which was independent of the DSB induced by CRISPR/Cas9. Similar distribution patterns were observed at 14 Mb ([S6B Fig](#pone.0225740.s006){ref-type="supplementary-material"}). To further evaluate this biased distribution pattern, we established two more DSBs (19 Mb-I and 19 Mb-II) close to each other, and the location of 19 Mb-I was centromeric to 19 Mb-II ([S6C Fig](#pone.0225740.s006){ref-type="supplementary-material"}). Again, both DSBs induced crossovers centromeric to the DSBs. The crossover points induced by 19 Mb-II was not observed for 19 Mb-I. These data implied that the biased distribution pattern was inherent and not influenced by the genome sequence or structure.

SNP array analysis reveals introduction of homozygosity telomeric to the DSB {#sec018}
----------------------------------------------------------------------------

The predicted outcome post-crossover in this study would be the same copy numbers (two copies) of the genome and homozygous SNPs telomeric to the DSB. This prediction was assessed by an SNP array. When the DSB was introduced at the 9 Mb position of chromosome 19, a homozygous SNP pattern was observed telomeric to the DSB on chromosome 19 (9 Mb) ([Fig 2D](#pone.0225740.g002){ref-type="fig"}).

BLM protein inhibitor ML216 has a similar effect on crossovers in chromosome 19 {#sec019}
-------------------------------------------------------------------------------

For hiPSC-mediated therapeutics, exogenous genetic materials are undesirable, such as the Tet-Off cassette in the *BLM* gene. We therefore also examined inhibitors of the BLM protein. Nguyen et al. reported that a small molecule inhibitor, ML216, shows strong selectivity for BLM in cultured cells \[[@pone.0225740.ref012]\]. More recently, Lazzarano et al. showed that ML216 induces mitotic crossover in mouse ESCs. They also reported that transient suppression of the BLM protein did not increase aneuploidy \[[@pone.0225740.ref013]\]. The procedure used to isolate positive clones generated with the BLM inhibitor ML216 is shown in [Fig. 3A](#pone.0225740.g003){ref-type="fig"}.

![BLM protein inhibitor ML216 has a similar effect on crossovers in chromosome 19.\
Procedure for the isolation of *N*^*R*^*P*^*R*^ clones under the condition of BLM protein inhibition. hiPSC-*BLM*^tet/tet^*AAVS1*^cNP/+^ cells were treated with ML216 from 12 h before transfection to 1 day after transfection. (B) Efficiency of crossover with ML216 treatment at the 9 Mb region of chromosome 19. Bar indicates SEM. (C) Distribution of the crossover points at 9 Mb under inhibition of the BLM protein by ML216. We picked 126 colonies (three trials) and performed genotyping ([S5 Fig](#pone.0225740.s005){ref-type="supplementary-material"}). Ten *N*^*R*^*P*^*R*^-positive clones were isolated and analyzed using LOH panels and SNP arrays. Open squares indicate the heterozygous genotype. Closed black squares indicate the loss of heterozygosity (LOH) genotype. DSBs introduced by the CRISPR/Cas9 system are shown by scissors. (D) SNP array analysis of hiPSC-*BLM*^*t*et/tet^*AAVS1*^cNP/+^ ML216(+)9M-CRISPR (+) cells. (E) Comparison of crossover points introduced by suppression of *BLM* transcripts (lanes 1 and 3) or inhibition of the BLM protein by ML216 (lane 2 and 4). DSBs were introduced at 14 Mb (lanes 1 and 2) or 19 Mb-I (lanes 3 and 4).ML216 was added at 0.5 day before transfection.](pone.0225740.g003){#pone.0225740.g003}

The efficiency of crossover with ML216 was similar to that with *BLM* transcript suppression and dox treatment ([Fig 3B](#pone.0225740.g003){ref-type="fig"}). The LOH panel and SNP array analyses showed in a similar pattern of suppression to that induced by the Tet-Off system ([Fig 3C and 3D](#pone.0225740.g003){ref-type="fig"}). The effect of ML216 was further evaluated by SNP array analyses at 14 Mb and 19 Mb-I, and a similar crossover pattern was observed ([Fig 3E](#pone.0225740.g003){ref-type="fig"}). We performed further SNP analyses with whole chromosomes and we found that the crossover only occurred at the predicted sites ([S7 Fig](#pone.0225740.s007){ref-type="supplementary-material"}).

Combination of BLM inhibitor ML216 and DSBs results in homozygosity of HLA class I genes in the short arm of chromosome 6 {#sec020}
-------------------------------------------------------------------------------------------------------------------------

Because HLA genes are highly polymorphic, most individuals have two HLA haplotypes, namely the HLA-heterozygous state. When established hiPSCs or their differentiated cells, which are most likely HLA-heterozygous, are used for therapeutics as donor cells, the recipient must have the same combination of HLA haplotypes. Our strategy is able to induce HLA homozygosity in the entire region of the HLA locus. Therefore, we can easily choose a much less incompatible combination between the donor of HLA-homozygous hiPSC-derived differentiated cells and recipient.

To generate HLA-homozygous hiPSCs, we inserted the cNP cassette into a piggyBac transposon vector within the telomeric region of the short arm of chromosome 6, where HLA genes are located (hiPSC-*telHLA*^*cNP/+*^). Then, we introduced an allele-specific DSB between HLA class I and III genes under inhibition of the BLM protein by ML216. The procedure used to isolate the HLA-homozygous clones is shown in [Fig 4A](#pone.0225740.g004){ref-type="fig"}, and the location of DSBs introduced by CRISPR/Cas9 and the HLA genotype in parental hiPSCs are schematically presented in [Fig 4B](#pone.0225740.g004){ref-type="fig"}.

![Combination of BLM inhibitor ML216 and DSBs equidistant to the HLA class III and I genes in the short arm of chromosome 6 results in homozygosity of HLA class I.\
(A) Procedure for the isolation of HLA-homozygous clones from hiPSC-*telHLA*^*cNP/+*^ cells under the condition of BLM protein suppression. (B) Schematic representation of the short arm of chromosome 6. After targeting the double selection cassette (*telHLA*^*cNP/+*^), an allele-specific DSB was introduced between HLA class I and III genes. The HLA-heterozygous genotypes in parental cells are shown in the right panel. (C) Schematic representation of the short arm of chromosome 6 after crossover. Patterns of heterozygous and LOH genotypes are shown in the left panel. HLA genotypes after crossover in clone 1 are shown in the right panel. (D) SNP array analysis of hiPSC-*telHLA*^*cNP/+*^ML216(+)HLA I-III-CRISPR(+). (E) Flow cytometry profile of the surface expression of the HLA-A haplotype A2 and A32 in hiPSCs.](pone.0225740.g004){#pone.0225740.g004}

We obtained two independent positive clones and analyzed the crossover points. Both crossover points were nearby and centromeric to the DSB ([Fig 4C](#pone.0225740.g004){ref-type="fig"}, left). The HLA genotypes were consistent with the crossover points ([Fig 4C](#pone.0225740.g004){ref-type="fig"}, right). SNP array analysis revealed a homozygous SNP pattern in the short arm of chromosome 6 telomeric to the DSB ([Fig 4D](#pone.0225740.g004){ref-type="fig"}), which was consistent with the pattern predicted post-crossover. We analyzed expression of marker genes for pluripotency and found that their expression in hiPS-*telHLA* ^*cNP/+*^ ML216(+) HLA I-III-CRISPR (+) was similar to that in hiPS-*telHLA* ^*cNP/+*^. These data suggested that the clones maintained pluripotency after crossovers ([S8 Fig](#pone.0225740.s008){ref-type="supplementary-material"}). To confirm the crossovers, we analyzed the surface expression of HLA class I molecules with a haplotype-specific monoclonal antibody against HLA-A ([Fig 4E](#pone.0225740.g004){ref-type="fig"}). hiPSC-*telHLA*^*cNP/+*^ expressed both A32 and A2 haplotypes ([S9 Fig](#pone.0225740.s009){ref-type="supplementary-material"}). In contrast, hiPSCs after crossover expressed only the A2 haplotype. We therefore successfully generated HLA-homozygous hiPSCs, and this strategy can be used for any human genomic region to induce homozygosity followed by functional genomics.

Discussion {#sec021}
==========

To establish HLA-homozygous hiPSCs, we used two genetic elements: the Tet-Off cassette to suppress *BLM* expression and the cNP cassette for positive selection. However, for hiPSC-mediated therapeutics, it is preferable to avoid the use of exogenous genetic elements. We therefore also demonstrated successful substitution of the Tet-Off cassette with a small molecule BLM inhibitor, ML216. In the future, we hope to evaluate the effects of ML216 on the human genome by next generation sequencing, because *BLM* suppression results in genome instability.

We cloned the cNP cassette into the piggyBac transposon vector that is removable by piggyBac transposase without any footprint after positive selection \[[@pone.0225740.ref014]\]. In addition, the cNP cassette was flanked by insulator sequences for its stable expression. By using the combination of the small molecule BLM inhibitor and piggyBac transposon vector, it may be possible to establish HLA-homozygous hiPSCs without any exogenous genetic elements.

Recently, Wang et al. reported Cas9-mediated chromosomal allelic exchange in mouse somatic tissue \[[@pone.0225740.ref015]\]. This novel technology resulted in the repair of compound heterozygous recessive mutations. However, unlike in our study, allelic exchange was expected to occur during the 2N phase, but not the 4N phase, so that any genomic region would not be homozygous.

HLA complex genes are located within the 6p21.3 region of the short arm of chromosome 6 and comprise more than 220 genes. Most of these genes are involved in immune functions. Because HLA genes are highly polymorphic, most individuals have two HLA haplotypes, i.e., the HLA-heterozygous state. When established hiPSCs or their differentiated cells, which are most likely HLA heterozygous, are used for therapeutics as donor cells, the recipient must have the same combination of HLA haplotypes. However, HLA matching between a donor and recipient is very rare. Therefore, a bank of HLA-homozygous hiPSCs has been generated \[[@pone.0225740.ref016]\]. For the HLA-homozygous bank, HLA-A, HLA-B, and HLA-DR were selected for matching, but not HLA-C, HLA-DQ, or the minor histocompatibility antigens \[[@pone.0225740.ref016]\]. In contrast, our strategy is able to induce HLA homozygosity across the entire region of the HLA locus. Therefore, using this strategy, one could easily choose a much more compatible combination between the donor of HLA-homozygous hiPSC-derived differentiated cells and the recipient \[[@pone.0225740.ref017]\]. Although careful examination of HLA-homozygous hiPSCs is needed for cancer predisposition and effectiveness of differentiation, they may facilitate hiPSC-based transplantation related to the immunological differences between donors and hosts.

Other approaches to reduce the immunogenicity of hiPSCs and their derivatives have included the generation of haplotype-specific HLA antigens or the complete deletion of HLA antigens \[[@pone.0225740.ref011]\] \[[@pone.0225740.ref018]\] with the latter being accomplished by deletion of the HLA gene itself or *B2M* gene targeting \[[@pone.0225740.ref019]\]. However, it has been shown that cells lacking HLA-C antigens are susceptible to attack by natural killer cells \[[@pone.0225740.ref019]\] \[[@pone.0225740.ref020]\], posing a possible shortcoming. More recently, Xu et al. reported that HLA-C-retaining hiPSCs with HLA-A and -B pseudo-homozygosity and HLA-A and -B knockout generated by CRISPR/Cas9 showed enhanced immune compatibility \[[@pone.0225740.ref021]\]. hiPSCs produced using this new method retained either one copy or no copies of HLA-A and -B. However, our strategy allows retention of two homozygous copies of all the HLA antigens, which is arguably a safer approach than deleting entire HLA antigens.

In conclusion, the method described in this study offers a novel genetic tool for human biology.

Supporting information {#sec022}
======================

###### Removal of the selection cassette.

\(A\) Schematic representation of the BLM locus before and after removal of the selection cassette. Primers hBLM-endF and hBLM-endR were used to detect the removal. (B) Analyses of colonies after Flpo transfection by PCR with primers hBLM-endF and hBLM-endR. The selection cassette was deleted in clones \#1 and \#2, but not in clones \#3--\#6. M indicates the marker.

(PDF)

###### 

Click here for additional data file.

###### Comparison of BLM transcripts between parental hiPSCs and hiPSC-*BLM*^*tet/tet*^ by RNA seq analyses.

FPKM derived from hiPSC-*BLM*^*tet/tet*^ was divided by that from hiPSCs.

(PDF)

###### 

Click here for additional data file.

###### Measurement of *BLM* transcripts after 8 days of dox treatment.

The method to detect BLM transcripts was the same as that in [Fig 1D](#pone.0225740.g001){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Efficiency of iCre-mediated cassette inversion.

hiPSC-*BLM*^*tet/tet*^*AAVS*^*cNP/+*^cells (5×10^5^) were transfected with EF1*α*-iCre or pBluescript (pBS), followed by selection with either 100 μg/mL G418, 0.75 μg/mL puromycin, or both. The efficiency of Cre-mediated cassette inversion was estimated at approximately 10 days after selection. Surviving colonies after the selections were fixed and stained with Giemsa stain. They are shown with blue dots.

(PDF)

###### 

Click here for additional data file.

###### Detection of positive clones bearing the crossover by genotyping of the AAVS1 locus in chromosome 19.

\(A\) Candidate clones were analyzed by competitive PCR using primers AAVS1-C-F, AAVS1-C-R, and Puro-L2 ([S1 Table](#pone.0225740.s010){ref-type="supplementary-material"}). hiPSC colonies after selection were picked up and applied to PCR analysis or culture in 96-well plates. (B) Wildtype, neomycin resistance, and puromycin resistance alleles are represented by bands of 275, 407, and 1435 bp, respectively. The band derived from the wildtype allele is indicated by an asterisk. The positive pattern losing the band derived from the wildtype allele is shown in lane 3. M indicates 100 bp markers.

(PDF)

###### 

Click here for additional data file.

###### Distribution of crossover points in chromosome 19.

\(A\) Analyses of crossover points in chromosome 19 (9Mb, 14Mb, and 19Mb). (B) LOH panel of crossover points at 14 Mb. (C) LOH panel of crossover points at 19 Mb-I and 19 Mb-II.

(PDF)

###### 

Click here for additional data file.

###### SNP array analyses of the whole genome.

SNP array patterns were the same in hiPSCs and two clones \[hiPSC-*BLM*^*tet/tet*^*AAVS*^*cNP/+*^DOX(+)9M-CRISPR(+) and hiPSC-*BLM*^*tet/tet*^*AAVS*^*cNP/+*^ML216(+)9M-CRISPR(+)\] after crossovers except in predicted sites (red box). hiPSCs had abnormal chromosomes 3 and 4 as indicated by a black box. These abnormalities might have occurred during hiPSC generation, because parental fibroblasts did not contain these abnormalities.

(PDF)

###### 

Click here for additional data file.

###### Quantification of pluripotency marker gene expression.

FPKM (fragments per kilobase of exon per million mapped reads) was calculated from total RNA of parental fibroblasts (1), hiPSC-*telHLA*^*cNP/+*^ (2), and hiPSC-*telHLA*^*cNP/+*^ML216(+)HLA I-III-CRISPR(+) (3). (n = 3, error bars show SEM).

(PDF)

###### 

Click here for additional data file.

###### Flow cytometry profile of the surface expression of HLA-A haplotype A2 and A32 in hiPSCs-*telHLA*^*cNP/+*^.

(PDF)

###### 

Click here for additional data file.

###### Primers used for vector construction and PCR genotyping.

(PDF)

###### 

Click here for additional data file.

###### Sequences of TALENs.

(PDF)

###### 

Click here for additional data file.

###### CRISPR information.

(PDF)

###### 

Click here for additional data file.

###### Primers used for SNP typing.

(PDF)

###### 

Click here for additional data file.
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Reviewer \#1: Yes

Reviewer \#2: Partly
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Yoshimura et al. have developed a new method to generate loss of heterozygosity (LOH) mutants in human induced pluripotent stems cells (hiPSCs).

This method is based on three components:

-Genetic or pharmacological inhibition of the Bloom helicase, which is known to result in hyper-recombination.

-CRISPR/Cas9 to cleave the genome at selected regions in an allele specific manner.

-A cassette for positive selection of LOH clones. As the Piggy bac system is used, these genetic manipulations leave no trace in the manipulated genome.

This ingenious strategy leads to a relatively high rate of LOH hiPSC clones. Authors have first validated their strategy on chromosome 19. Then, they managed to obtain LOH clones for some HLA genes on the short arm of chromosome 6. This is promising to increase histocompatibility, an important hurdle for hiPSCs-based cell therapy.

The objective of the study is clearly stated and the methods are scientifically sound.

The manuscript is well written. Overall, this is a very interesting study and I have only minor suggestions.

1.It would be interesting to analyse more independent clones (only 2 clones were analysed) for experiments on HLA (Figure 4).

2.It would have been interesting to measure whether pluripotency markers (POU5F1, NANOG, alkaline phosphatase activity...) are affected in manipulated cells.

3.If I am right, the double selection requires an inversion of the selection cassette and the use of a CRE. You mention that you used an iCRE but I have not understood well what drives the expression of the CRE and how efficient it is. Could you please comment on that and be more explicit?

4.Why starting the puro treatment before G418?

5.Even if out of the scope of this study it will be interesting to know whether LOH occurs in other unwanted DNA regions. The selection cassette permits to select for positive clones but this does not mean that other regions are not affected due to over recombination?

6.Line 443. It is mentioned that DSBs were either induced by CRIPSR/Cas9 or by TALEN. I thought that authors had only used CRIPSR/Cas9?

7.In fig.2C, clone 25, which behaves very differently from all other clones, is marked by an \* but this particular clone is not commented.

8.Lines456. There are legends for panels E and F but these panels are missing in the figure.

9.Line 461. Change 'suppression' for inhibition as ML216 inhibits DNA binding and blocks BLM helicase activity, protein suppression let think that the protein is destroyed.

Reviewer \#2: In this manuscript, Yoshimura and collaborators established a system to induce chromosomal crossover through suppression of BLM, by means of a Tet-off regulatory system or treatment with the small molecule inhibitor ML216, along with allele-specific double strand breaks induced by CRISPR/Cas9 in human pluripotent stem cells. Clones in which crossover was successfully achieved were selected through a conditionally convertible selection cassette. The authors then used this elegant approach to target chromosome 19 and 6, which resulted in homozygosity of the targeted regions as shown by SNP array analysis. Lastly, the authors showed a potential application of this approach as they induced homozygosity of HLA class I genes, which was evidenced by FACS analysis.

Although the ultimate goal of inducing crossover and selecting positive clones was achieved, as demonstrated by SNP analyses, there are major concerns in this work (see detailed description below). In this reviewer's opinion, the most critical concern is the lack of controls and omission of experimental results. This does not allow the reader to perform a critical analysis of the work and leads to solely relying on the author's description and schemes. Other concerns are related to manuscript structure, as the authors do not provide a clear rational on the gene editing strategy they followed and simply refer the reader to a previous publication (Yusa et al, Nature, 2004) which also lacks of detailed information or description of the system. This is important, as the reader should be able to understand at least the rational of the genetic engineering performed, especially if one is not familiar with previous publications on the approach used. An example is that the authors do not mention whether expression of tTA for BLM Tet-off system is under the native BLM promoter and the reader has to assume it. Another important aspect is that the authors do not acknowledge the limitations of their approach. For instance, as pointed out below, efficiency seems to be extremely low and there is no discussion about it. Moreover, authors should discuss that LOH has also been extensively associated with cancer. This is particularly relevant as the authors propose the use of their approach in regenerative medicine. Overall, this is an interesting study that could be highly improved if the authors include more experimental data and controls.

Specific observations:

1\. The abstract does not provide a clear idea of the importance of the study. It starts suggesting that LOH can be used to identify genes associated with loss or gain of disease phenotype, but after describing the approach, it says that the system is useful in regenerative medicine. In this regard, it is clear that the approach is useful as a tool for genetic analysis, but in this reviewer's opinion, the authors may want to reconsider suggesting its use in regenerative medicine as chromosomal crossover can cause genetic instability and it has been associated with cancer.

2\. In the abstract, authors claim that ML216 treatment had similar crossover efficiency than Tet-Off-driven BLM suppression but there is no actual data to compare "efficiency". Instead, both approaches successfully promoted crossover.

3\. In author summary, authors once again suggest that chromosomal crossover might be useful for stem cell-based therapy. Consider revising this, otherwise authors should include in discussion association of crossovers with cancer or other potential limitations of the approach.

4\. Introduction does not state clearly the relevance of the study or the utility of the approach. Instead, authors claim that it has been tested in other cell types/species but not in hiPSCs.

5\. In line 211, authors mention that the CMV promoter was changed to hEF1a but the diagram on Fig. 1B still shows the CMV promoter.

5\. It is not mentioned whether tTA is expressed under the native BLM promoter. If this is the case, it makes sense that BLM expression in parental and BLMtet/tet lines (No Dox) is similar. However, since this cassette is largely used in the study, it would be important to include this expression comparison.

7\. Authors do not show experimental evidence on the removal of Pgk-Puro cassette used to select BLMtet/tet clones, this is critical as the authors rely on an additional positive Puro selection to identify crossover.

6\. In line 91, authors describe that "Upon Cre expression, inversion of the cNP cassette occurred, resulting in loss of G418 resistance and gain of puromycin", however, no experimental data are shown. This is a constant along the manuscript that needs to be addressed. This is important as the reader can get an idea of the efficiency of the system to induce inversion of the selection cassette.

7\. In Fig. 1B, authors show a bar graph in which about 3 clones out of 1e6 cells were positive for the double (Puro/Neo) selection. Although this suggests that crossover was successfully achieved, the authors should comment on the low efficiency of the approach, which might be explained by all the variables in the system (e.g. Dox incubation, DSB in 4n phase etc).

8\. There is no explanation on why the authors performed the experiments after 7 days with Dox (only two time points were analyzed for BLM expression, 5d and 7d).

9\. In line 130, authors mention that when crossover occured centromeric to DSBs, the distance between the crossovers and DSBs was small. Then, a similar pattern is observed at 14Mb from centromere. However, according to Fig.2C, it seems that only one clone out of 25 resulted in crossover centromeric to the DSB (and one out of six in Fig. S2B). Are these numbers sufficient to conclude a "pattern" of centromeric vs telomeric crossover proximity?

10\. Figure 2 legend has (E) and (F) but this is not shown in the figure.

11\. The authors do not include any data on how effective the ML216 treatment is in their experimental setting.

12\. Materials and methods say that ML216 was used 12h before transfection but figure legend (line 462) says that treatment began 24h before transfection.

13\. Although a similar pattern of SNPs is observed between Tet-off and ML216, there is no data on the efficiency of ML216 treatment (how many positive clones?).

14\. Fig 3C hiPS-BLMtet/tetAAVS1cNP/+ and Fig. 2D (same condition) are identical. If the same SNP analysis in Fig 2D was used as a reference for Fig 3C, it should be mentioned in the text to avoid misleading interpretation of intentional image duplication. Ideally, however, each assay (Fig 2D and 3C) should have been run in parallel with its own negative control.

15\. In Fig. 3, ML216 treatment is used in cells that have the BLMtet/tet cassette. Again, showing that cassette insertion (No Dox) does not modify itself BLM expression would avoid concerns on the cassette background.

16\. In Fig.4C, directionalities of the chromosome, DSB and crossover are confusing. The chromosome diagram shows that Tel is top and Cent is bottom, while this seems to be the opposite in the DSB diagram next to it?

17\. Fig. 4E shows parental cells positive for HLA-A32 and HLA-A2. However, it would be more important to show the cells that were edited to include the selected cassette but did not have ML216 treatment (negative control). Furthermore, authors claim that these cells are HLA-homozygous hiPSCs without exogenous genetic elements (line 180) while no data show that the selection cassette was removed.

18\. It would be useful to see whether the hiPSCs retained pluripotency after chromosomal crossover and all the genetic editing that they were subjected to.

19\. Other experimental approaches such as FISH or Southern blot would provide more solid evidences on the crossover efficiency, cassette integration/removal, transposon removal etc.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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Thank you for the revised version. Please consider it to be accepted in principle.

However, Reviewer 2 points out several minor editorial issues. Please submit a revised final version incorporating those minor edits.
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**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors have adequately addressed my comments in their revised manuscript.

The manuscript is technically sound, and the data support the conclusions.

SNP array datasets are available in GEO.

The manuscript is very well written and intelligible.

Reviewer \#2: Yoshimura et al have submitted a modified version of the manuscript entitled "Generation of targeted homozygosity in the genome of human induced pluripotent stem cells". In this new version, the authors have addressed most of the reviewer's observations and concerns. Importantly, in this new submission the authors have included data that better support their statements. This also facilitates the analysis and understanding of the experiments performed. There are still a few observations on the current version that the authors may consider revising (see below), but overall, in this reviewer's opinion, the manuscript is now suitable for publication.

1\. Supplementary Figure 4 legend does not explain what the blue staining means, which is essential to understand the iCre-mediated cassette inversion selection.

2\. In line 88, authors claim that efficiency of inversion was 20%-30% but it is not clear what they measured to obtain this number.

3\. In line 134, revise "we established a two more DSBs" for "we established two more DSBs".

4\. In S6 Fig A-C consider changing M for Mb to be consistent with the text (eg. 9Mb, 14Mb, 19Mb-I)

5\. In line 157, the authors start describing the generation of HLA-homozygous iPSC. This seems out of context since the rational of doing it is not mention in the introduction nor in the results section. Maybe a few sentences describing why the authors were interested on achieving HLA homozygosity in hiPSCs would make it easier for the reader to understand this section.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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The reviewer\'s comments (especially \#2) are very nice and constructive. I was very impressed.

I will submit manuscript again in future.
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Submitted filename: Response to the Reviewer 1105.docx
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Click here for additional data file.
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PONE-D-19-19663R2

Dear Dr. Takeda,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Michael Kyba

Academic Editor

PLOS ONE
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PONE-D-19-19663R2

Generation of targeted homozygosity in the genome of human induced pluripotent stem cells

Dear Dr. Takeda:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Kyba

Academic Editor

PLOS ONE
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